• TSPAN18–STIM1 Signaling in Prostate Cancer Bone Metastasis

  2026-09-09

  Zhou et al. identify TSPAN18 as a stabilizer of STIM1 that limits TRIM32-mediated ubiquitination and amplifies store-operated calcium entry in prostate cancer. The study connects this protein-quality-control mechanism to migration, invasion, bone metastasis, and adverse clinical features, providing a mechanistic framework for prostate cancer research.

• Escitalopram Assay Design: From 5-HTT to Translation

  2026-09-09

  Escitalopram research is strongest when transporter potency, assay context, and clinical moderators are interpreted together. This guide connects Lexapro pharmacology with practical 5-HT reuptake inhibition workflows and the limitations of augmentation evidence.

• Thiothixene: Neuroimmune Assay Workflows

  2026-09-08

  Thiothixene supports a practical bridge between dopamine receptor pharmacology and in vitro macrophage efferocytosis enhancement. This guide translates its Stra6l–vitamin A–arginase 1 biology into reproducible assay steps while keeping schizophrenia treatment and FGFR1-related findings appropriately distinct.

• Dasatinib: From Kinase Signals to Tumor State

  2026-09-08

  Dasatinib (BMS-354825) is more than a Bcr-Abl research tool. Its Src-family kinase activity creates a framework for connecting phosphorylation events with EMT, stemness, adhesion, invasion, and metastatic behavior—while the SNAI1–PIK3R2/p-EphA2 study shows why pathway and cell-state measurements must be interpreted together.

• Tropisetron Hydrochloride: Applied Assay Guide

  2026-09-07

  Tropisetron Hydrochloride supports integrated studies of 5-HT3 receptor signaling, α7-nicotinic receptor activity, and renal organic-cation transport. This workflow-centered guide shows how to pair receptor assays with OCT2/MATE1 models while avoiding concentration, solubility, and cell-system artifacts.

• BRCAness and Olaparib Sensitivity in Mesothelioma

  2026-09-07

  Borchert et al. linked homologous recombination repair defects, or BRCAness, with olaparib sensitivity in malignant pleural mesothelioma, particularly in BAP1-mutated models. Their combination of drug-response experiments and clinical-sample gene-expression profiling provides a useful framework for biomarker-guided cancer chemotherapy research while emphasizing the need for prospective validation.

• Recombinant Human FGF-19: Applied Assay Workflows

  2026-09-05

  Build more reproducible receptor-binding, proliferation, and metabolic signaling experiments with a validated, tag-free FGF-19 reagent. This guide connects practical protein handling to exploratory studies of FGFR4 signaling and the WIP1–p38 MAPK–pyroptosis axis in renal injury.

• D-N-Acetylgalactosamine: Lab Guide

  2026-09-04

  D-N-Acetylgalactosamine (SKU B7904) provides a defined, high-purity carbohydrate metabolite for aqueous or DMSO-based work involving glycoprotein composition and glycosylation pathway studies. It should not be selected for ethanol-based protocols or long-term storage of working solutions.

• Escitalopram Workflows for Anxious Depression

  2026-09-04

  Build reproducible serotonergic assays around Escitalopram, from transporter occupancy and 5-HT reuptake inhibition to anxiety-relevant phenotyping. A reference-study translation shows how subgroup stratification and orthogonal endpoints can distinguish target engagement from clinically meaningful behavioral effects.

• Zolmitriptan: From Receptor Biology to Translation

  2026-09-03

  Zolmitriptan is more than a familiar serotonergic tool: it is a precise entry point for studying receptor-driven vascular and neuropeptide biology in migraine and cluster headache models. This thought-leadership analysis outlines how to build stronger assays around a 5-HT1B receptor agonist, use lysosomal biology as a carefully bounded cross-domain lens, and convert compound handling, mechanistic validation, and translational decision gates into a more reliable research strategy.

• Levofloxacin: From DNA Gyrase to Translation

  2026-09-03

  A translational framework for using Levofloxacin to connect bacterial DNA replication, antimicrobial resistance surveillance, and bone and cartilage cell biology.

• Trelagliptin, RUNX2, and Osteoblastic Differentiation

  2026-09-02

  The reference study identifies a potential bone-forming action of the DPP-4 inhibitor trelagliptin in MC3T3-E1 osteoblastic cells, linking treatment to AMPK activation, RUNX2 upregulation, and enhanced mineralization. Its findings provide a mechanistic starting point for osteoporosis research, while the in vitro design requires validation in primary cells and animal models.

• LNP-mRNA Fibroblasts for Intervertebral Disc Degeneration

  2026-09-02

  A 2026 Chemical Engineering Journal study developed fibroblasts engineered with lipid nanoparticle-delivered mRNA to produce TNF-α-neutralizing antibodies in degenerating intervertebral discs. The approach combines a local cell-based depot with transient mRNA delivery, reducing inflammatory injury and improving disc structure in a rat model while leaving important translational questions unresolved.

• Palonosetron hydrochloride: 5-HT3 Assay Workflows

  2026-09-01

  Build reproducible 5-HT3A/5-HT3AB receptor assays, transporter studies, and translational antiemetic experiments around a highly selective reference compound. This guide connects low-nanomolar receptor pharmacology with OCT2/MATE1 inhibition while emphasizing controls, dosing logic, and troubleshooting.

• Perospirone Workflows for Receptor and Kv1.5 Studies

  2026-09-01

  Build receptor-based schizophrenia research assays and vascular ion-channel workflows around Perospirone, also known as SM-9018 free base. Its established 5-HT2A, D2, and 5-HT1A pharmacology now pairs with a reported Kv1.5-linked coronary smooth-muscle effect, enabling a practical cross-domain safety screen.

7910 records 1/528 page Next 12345 下5页 Last page